The U.S. Court of Appeals for the Seventh Circuit has scheduled oral arguments for September 24, 2026, in the consolidated cases of Eli Lilly and Company v. Robert F. Kennedy Jr., a dispute that could reshape how emerging peptide therapies are classified under federal law.
At issue is whether retatrutide, an investigational therapy, should be classified as a biologic rather than a conventional drug. The FDA determined that retatrutide is a conventional drug, a decision Eli Lilly is challenging. The case centers on whether retatrutide’s molecular structure and manufacturing process qualify it for 12-year exclusivity under the Biologics Price Competition and Innovation Act (BPCIA).
The outcome carries significant implications for compounding pharmacies, telehealth platforms, and consumers. If retatrutide is deemed a biologic, it would generally be ineligible for pharmacy compounding and receive 12 years of market exclusivity, compared to five years for a conventional drug.
What happened
The Seventh Circuit will hear oral arguments on September 24, 2026, in the consolidated cases of Eli Lilly and Company v. Robert F. Kennedy Jr. The case challenges the FDA’s determination that retatrutide is a conventional drug rather than a biologic.
The legal dispute centers on whether retatrutide’s molecular structure and manufacturing process qualify it for 12-year exclusivity under the BPCIA. Eli Lilly contests the FDA’s classification, arguing that retatrutide should be treated as a biologic.
Retatrutide remains investigational and is not FDA-approved.
Why it matters
The Seventh Circuit’s ruling will resolve whether retatrutide receives 12-year biologic exclusivity, which would bar compounded versions for over a decade and set binding precedent across multiple federal circuits.
A win for Eli Lilly could fundamentally reshape the economics of peptide compounding and establish a more favorable regulatory framework for future peptide biologics. Affected groups include:
- Eli Lilly — seeking biologic classification and extended exclusivity
- Compounding pharmacies — biologic status would generally make retatrutide ineligible for compounding
- Telehealth platforms — access to lower-cost versions could narrow if Lilly prevails
- Peptide consumers — exclusivity could limit access to more affordable alternatives
- Generic drug manufacturers — biologic classification extends the timeline for competing products
The case also carries broader significance. A ruling in Eli Lilly’s favor could establish precedent for how future peptides are classified, potentially influencing regulatory strategy across the pharmaceutical industry.
What to watch next
- Oral arguments on September 24, 2026, before the Seventh Circuit
- The court’s subsequent ruling, which will determine retatrutide’s classification
- Whether the losing party appeals the decision further
- How the ruling influences FDA’s approach to classifying future peptide therapies
- Potential impact on compounding access if retatrutide later receives FDA approval
Sources
Reason.com — “Can a New Weight-Loss Treatment Escape the Legal and Regulatory Thicket?”
Industry information only. Not medical or legal advice.
